Autres langues Zai Lab Limited Hong Kong S.E.

Actions

9688

KYG9887T1168

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:32 18/09/2026			Varia. 5j.	Varia. 1 janv.
20,58 ^HKD	+4,47 %		+8,66 %	+50,77 %

04/09	Les actions asiatiques cotées aux États-Unis sous forme d'ADR s'inscrivent en légère baisse lors de la séance de vendredi	MT
02/09	Les actions asiatiques cotées aux États-Unis sous forme d'American Depositary Receipts progressent lors de la séance de mercredi	MT

Autres langues

04/09	Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading
02/09	Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
31/08	Asian Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
28/08	Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up 2% for Week
26/08	Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%
25/08	Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
19/08	Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
17/08	Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
17/08	Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis
13/08	Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading
11/08	Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
07/08	Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; End Week Up 2%
06/08	Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
06/08	Zai Lab Shares Rise After Q2 Beat
06/08	Zai Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Revenue $106.3M, vs. FactSet Est of $103.9M
06/08	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Loss of $0.46 per ADS, vs. FactSet Est of $-0.68
06/08	Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
03/08	Zai Lab Receives FDA Orphan Drug Designation for Zocilurtatug Pelitecan in Neuroendocrine Carcinomas
03/08	U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
29/07	Asian Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
22/07	Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
29/06	Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing
17/06	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas
16/06	Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug